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Background !
We report here our discovery and whole genome sequencing 
(WGS)  analysis  of  a  family  with  dominantly  inherited 
familial  dysautonomia  (Figure  1).  The  mother  is  affected 
with  dysautonomia,  hereditary  hemochromatosis,  and 
obsessive  compulsive  traits.  The  oldest  daughter  reports 
severe  dysautonomic  syncopal  episodes,  gastroparesis, 
glaucoma,  visual  and  auditory  hallucinations,  urinary 
retention,  and  one  prior  stroke.  One  son  is  affected  with 
dysautonomia,  Tourette  syndrome  (TS),  attention  deficit 
disorder (ADD), and obsessive-compulsive disorder (OCD). 
Another  son  reports  dysautonomia,  asthma,  seizure  in 
response to pertussis, dyslexia, migraine, dysgraphia, ADD, 
sensory integration disorder, and arthritis. !
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Methods !
WGS was performed on two affected siblings in the Illumina CLIA-
certified lab. Three other DNA samples from the family also underwent 
WGS in the research setting at CSHL. DNA samples from the same five 
people were genotyped using the Illumina HumanOmni2.5-8 BeadChip. 
Genome-wide parametric linkage analysis was performed using Merlin 
(adjusted for linkage disequilibrium). Our group previously reported the 
low concordance rates across different variant calling pipelines. Thus, to 
reduce algorithm-induced biases, we used multiple pipelines for quality 
control,  alignment,  assembly,  variant  calling,  genotype  refinement, 
variant  filtering,  and  variant  annotation  (Figure  2).  The  Empowered 
Genome Cohort data,   implemented in the Ingenuity variant analysis 
system,  was  also  used  to  filter  out  WGS-specific  sequencing  errors, 
which might have been identified as rare variants. !
Results  !
Linkage  analysis  showed  not  enough  power  for  identifying  any  disease 
relevant variant loci in a single family. None of the family members carry 
any previously reported variants in IKBKAP that have been implicated in the 
autosomal recessive transmission of familial dysautonomia. The WGS data 
had good sequence coverage for IKBKAP in all five people (mean coverage 
~40x) but we did not identify any novel rare variants in this gene. ERDS and 
PennCNV did not reveal any CNVs that of relevance to the phenotype of 
familial dysautonomia. We have generated a list of rare variants of unknown 
significance (Table 1 & 2). Sanger sequencing results confirmed an insertion 
in  POU4F1  (Figure  4).  We  find  relatively  low  concordance  across  three 
variant detection pipelines (Figure 5). Pharmacogenomic analyses reveal the 
recommended dosages of Coumadin and Simvastatin (Table 3). Five variants 
in three people with prior clinical evidence are also shown (Table 4).!
Conclusions!
Here  we  show one  example  of  individualized  medicine  in  a  family  with 
neuropsychiatric symptoms and at least two rare diseases. WGS data provides 
much more clinically relevant and potentially actionable information when 
compared to genotyping arrays. Despite limited overall agreement between 
CLIA certified and non-CLIA certified analysis pipelines, utilizing variants 
identified by two or more pipelines enables WGS to act as a useful technique 
for clinical diagnostics. For rare diseases, we argue that family history and 
other  family  members’  sequencing  data  should  be  incorporated  into 
downstream analyses so as  to  eliminate false positive findings of  disease-
associated variants. We highlight the importance of detailed phenotyping and 
sharing  of  both  genomic  and  phenotyping  data  because  of  extreme 
heterogeneity  across  families  and  insufficient  knowledge  of  rare  diseases. 
Ongoing effort will focus on identifying and proving familial dysautonomia 
relevant  variants,  extending  the  pharmacogenomic  analyses  to  the  other 
people in the pedigree, and including more family members in our study.!
Questions? Email: GholsonJLyon@gmail.com!
Figure 2. The left-hand side is the major analysis work flow while the right-hand side are the details of each 
procedure.* CADD (Combined Annotation Dependent Depletion, in press) : http://cadd.gs.washington.edu/ !
* Scalpel (in preparation) : Haplotype Micro-assembly for accurate INDEL detection: http://schatzlab.cshl.edu/!
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Figure 1. The pedigree in this study. The numbers below the children are their 
corresponding ages. Five people in the family have thus far been included in our WGS 
study: the parents, the 24-year-old daughter, the 17-year-old son, and the 15-year-old 
daughter.!
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Figure 5. Venn diagrams of the variant calling results across three independent alignment and assembly 
combinations. 2x100 paired end reads for the WGS data were generated on Illumina HiSeq2000 platform. 
Reads were mapped to the hg19 reference genome. BWA-0.7.5a, GATK v.2.6-5, ELANDv2e, and CASAVA 
1.8 were used here. (A) The Venn diagram is for SNP detection comparison. We noticed an even lower 
concordance rate compared to what we previously reported (57.4% across 5 pipelines). This is because we 
here use three different alignment steps. (B) The Venn diagram is for INDEL detection, the concordance rate 
is even lower: 40.6%. We focus on variants called by at least two pipelines, i.e. the central region surrounded 
by the red dash lines. This allows us to analyze 82.6% of the SNPs and 72.9% of the INDELs in our 
downstream analyses. !
(A)! (B)!
Table 3. Recommended dosages for Coumadin and Simvastatin dosages based on the oldest daughter's WGS 
results, in comparison to what she was actually prescribed in the absence of any genetic testing. 
Pharmacogenomics analyses were performed based on guidelines and algorithms from the International Warfarin 
Pharmarcogenomics Consortium (IWPC) and the Clinical Pharmacogenomics Implementation Consortium (CPIC) 
in the PharmGKB database. People who are homozygous for major alleles at both sites in CYP2C9 are designated 
as *1/*1. !
Table 1. A subset list of rare variants (MAF < 1%) found in at least two affected people. 
These variants are called by at least two pipelines, within coding regions, with a high 
VAAST score, and a CADD c-score greater than 20. !
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Table 2. The insertion in POU4F1 is found in two children with familial dysautonomia. 
There is no coverage in the mother’s WGS data. Follow-up Sanger sequencing confirmed 
the existence of the homozygous insertion in all three people : affected mother, affected 
daughter, and affected son. POU4F1 encodes a member of the POU-IV class of neural 
transcription factors. This protein is expressed in a subset of retinal ganglion cells and 
may be involved in the developing sensory nervous system.!
Table 4. At least seven mutations with substantial clinical relevance were found in our study. The “Daughter” means 
the oldest daughter, and the “Son” means  the 17-year-old son. “hom” = homozygous and “het” = heterozygous. 
“WT” = wild type. The mother is homozygous for the C282Y variant in HFE, and, consistent with the lack of 
symptoms for hemochromatosis in the children, we found that all three children are carriers for the C282Y variant, 
but not carrying any other reported hemochromatosis related variants. !
Figure 4. Sanger sequencing results confirmed the homozygous insertion in exon 2 of 
POU4F1. Sanger sequencing results of (A) the mother, (B) the oldest daughter, and (C) 
the 17-year-old son.!
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EPS15 chr1:51829571 Gly>Arg
Heterozygous
non-synon
197
47:24:23 Unknown
MYL7 chr7: 44179406 Gly>Ser
Heterozygous
non-synon
71
23:16:7 Unknown
ERI1 chr8: 8865561 Pro>Ser
Heterozygous
non-synon
156
49:30:19 Unknown
CCIN chr8: 36170317 Arg>Gln
Heterozygous
non-synon
223
36:14:22 Unknown
PCTP chr17: 53844742 Cys>Tyr
Heterozygous
non-synon
223
47:22:25 Unknown
Gene Chr Position Region Transcript Variant Protein Variant Inferred Activity
POU4F1 13 79176323 Exonic c.484_486dipGGC p.162_163_ins Loss
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Abstract!
!
Background:  We describe a whole genome sequencing study of  one 
family containing two affected male children,  aged 10 and 12,  with 
severe intellectual disability, autism-like behavior, and very distinctive 
facial  features.  High  accuracy  is  of  paramount  importance  in  the 
context of detecting or discovering the genetic influencers of human 
disease, yet each sequencing and analysis pipeline is still imperfect.  In 
this study, we leverage data from two sequencing platforms and many 
data processing and downstream analysis pipelines to more confidently 
identify variants that may play an influential role in the disease state of 
these two children.!
Presentation of the phenotype!
!
The  propositi  are  two  affected  male  brothers  (Fig.  1),  aged  10  and  12 
respectively,  with  severe  intellectual  disability,  autism-like  behavior, 
attention  deficit  issues,  and  very  distinctive  facial  features  (Fig.  1), 
including  broad,  upturned  nose,  sagging  cheeks,  downward  sloping 
palpebral fissures, relative hypertelorism, high-arched palate, and prominent 
ears.  Their  parents are nonconsanguineous and are both healthy,  and the 
family history does not demonstrate any members with anything resembling 
this current syndrome.!
Fig. 1  Facial phenotype of the younger brother at age 19 month  (A), 
3.5 years (a) and 7 years (a) ; and the elder brother at age 3 years (B), 5 
years  (b)  and  9  years  (b).   A  pedigree  displaying  intra  familial 
relationshi s.!
!
Complete Genomics WGS!
!
Whole  genomes  of  the  mother,  father  and 
both  affected  boys  were  sequenced  and 
analyzed  with  the  Complete  Genomics 
WGS  sequencing  and  bioinformatics 
pipeline.  Reads  were  mapped  to  the 
Genome  Reference  Consortium  assembly 
GRCh37.  Due  to  the  proprietary  data 
formats,  all  the  sequencing  data  QC, 
alignment  and  variant  calling  were 
performed by CG as part of their sequencing 
service,  using  their  version  2.0  pipeline. 
Complete Genomics WGS was optimized to 
cover 90% of the exome with 20 or more 
reads  and 85% of  the  genome with  20 or 
more reads. !
Illumina WGS!
!
Whole  genomes  of  the  entire  pedigree 
were  sequenced  using  the  Illumina 
HiSeq2000.  WGS  covered  >90%  of  the 
genome with 30 reads or more and with 
>80% of the bases having a quality score 
of >30. Illumina reads were mapped to the 
hg19  reference  genome  using  BWA  v. 
0.6.2-r126,  and  variant  detection  was 
performed using the GATK v.  2.4-9.   A 
second  analytical  pipeline  was  used  to 
map reads to the hg19 reference genome 
using  Novoalign,  and  variants  were 
detected using the FreeBayes caller. !
Methods: Whole genome sequencing (WGS) was performed on ten members of 
this family using the Illumina HiSeq2000 platform, with four (the two affected 
boys  and  their  parents)  being  additionally  sequenced  using  the  Complete 
Genomics (CG) WGS platform. CG data analysis was performed by CG, using 
their version 2.0 pipeline. Illumina reads were mapped to the hg19 reference 
genome using BWA v.0.6.2-r126, and variant detection was performed using 
the GATK v. 2.4-9. A second analytical pipeline was used to map the Illumina 
reads and detect variants using Novoalign and the FreeBayes caller. Disease 
variant  discovery  procedures  included  traditional  filtering  techniques  (using 
ANNOVAR  and  Golden  Helix  SVS),  and  a  statistical  framework  for 
identifying the likely disease causing variants (using VAAST). !
Results: CG WGS covered >85% of the genome and >90% of the exome, 
both with 20 or more reads. Illumina WGS covered >90% of the genome 
with 30 reads or more and with >80% of the bases having a quality score of 
>30. We found a ~2 to 5-fold difference in the number of variants detected 
as being relevant for various disease models when using different sets of 
sequencing data and analysis pipelines. In one instance, employing a ‘quad’ 
study design reliably identified three putative variants that followed an X-
linked disease model, in TAF1, ZNF41 and ASB12 respectively.  However, 
ZNF41 and ASB12 variants were subsequently found to be false positive 
findings  when  the  study  expanded  to  include  more  family  members  and 
more data from each. !
Bioinformatics analysis!
!
Bioinformatics  analyses  of  multiple  disease  model  pathways  were  performed in 
order  to  prioritize  and  identify  any  putative  mutations  that  might  aid  in  better 
understanding the pathogenesis of the described syndrome. We performed analyses 
to interrogate variants conforming to a de-novo, autosomal recessive and x-linked 
model of disease transmission. !
!
We used several methods to prioritize and identify potentially disease contributing 
germ-line  mutations,  including  VAAST,  Golden  Helix  SVS,  ANNOVAR  and 
CADD,  a  integrative  tool  for  scoring  single  nucleotide  variants  and  insertion/
deletions.  VAAST employs a likelihood-based statistical framework for identifying 
the most likely disease contributing variants given genomic makeup and population 
specific  genomic  information.    SVS  and  ANNOVAR  employ  more  traditional 
filtering techniques that leverage data stored in public genomic databases.!
Conclusions: Using ultiple sequencing and bioinformatics pipelines provides greater 
power in reducing false positive findings in the context of WGS studies - biological 
conclusions can shift between sequencing smaller to larger portions of a family.!
Using information from a greater portion of the family structure: 
17726 Variants were found to be de-novo in the two affected boys  
40 were coding : 
32 non-synonymous missense 
3 splicing  
2 frame-shift deletions 
1 stop-loss 
1 frame-shift insertion 
1 frame-shift substitution 
2824 Variants were found to conform to an X-linked disease model 
4 were coding: 
3 non-synonymous missense 
1 splicing 
Using only nuclear family: 
55195 Variants were found to be de-novo in the two affected boys  
122 were coding : 
107 non-synonymous missense 
4 splicing  
3 frame-shift deletions 
3 frame-shift insertions 
2 frame-shift substitutions 
2 stop-gain  
1 stop-loss 
26514 Variants were found to conform to an X-linked disease model 
28 were coding: 
27 non-synonymous missense 
1 splicing 
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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Figure 1 Sagittal and transverse computed tomography (CT) images of the brain and skull ofMA.We
show here sagittal and transverse sections taken from CT scans. Imaging was performed before (A) and
after (B) MA received deep brain stimulation surgery for his treatment refractory OCD. Two deep brain
stimulator probes can be seen to be in place from a bifrontal approach (B), with tips of the probes located
in the region of the hypothalamus. Leads traverse through the left scalp soft tissues. Streak artifact from
the leads somewhat obscures visualization of the adjacent bifrontal and left parietal parenchyma. We did
not observe any intracranial hemorrhage, mass eVect or midline shift or extra-axial fluid collection. Brain
parenchyma was normal in volume and contour.
DBS implant has contributed to any of these issues. Attempts to add fluoxetine at 80 mg
by mouth daily for two months to augment any eYcacy from the DBS and ERP were
unsuccessful, mainly due to no discernible benefit and prominent sexual side eVects. MA
still receives an injection of 37.5 mg risperidone every two weeks for his past history of
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ABSTRACT
Background. In recent years, there has been an explosion in the number of technical
and medical diagnostic platforms being developed. This has greatly improved our
ability to more accurately, and more comprehensively, explore and characterize
human biological systems on the individual level. Large quantities of biomedical
data are now being generated and archived in many separate research and clinical
activities, but there exists a paucity of studies that integrate the areas of clinical
neuropsychiatry, personal genomics and brain-machine interfaces.
Methods. A single person with severe mental illness was implanted with the
Medtronic Reclaim® Deep Brain Stimulation (DBS) Therapy device for Obsessive
Compulsive Disorder (OCD), targeting his nucleus accumbens/anterior limb of the
internal capsule. Programming of the device and psychiatric assessments occurred
in an outpatient setting for over two years. His genome was sequenced and vari-
ants were detected in the Illumina Whole Genome Sequencing Clinical Laboratory
Improvement Amendments (CLIA)-certified laboratory.
Results. We report here the detailed phenotypic characterization, clinical-grade
whole genome sequencing (WGS), and two-year outcome of a man with severe
OCD treated with DBS. Since implantation, this man has reported steady improve-
ment, highlighted by a steady decline in his Yale-Brown Obsessive Compulsive Scale
(YBOCS) score from⇠38 to a score of⇠25. A rechargeable Activa RC neurostimula-
tor battery has been of major benefit in terms of facilitating a degree of stability and
control over the stimulation. His psychiatric symptoms reliably worsen within hours
of the battery becoming depleted, thus providing confirmatory evidence for the
eYcacy of DBS for OCD in this person.WGS revealed that he is a heterozygote for the
p.Val66Met variant in BDNF, encoding a member of the nerve growth factor family,
and which has been found to predispose carriers to various psychiatric illnesses.
He carries the p.Glu429Ala allele in methylenetetrahydrofolate reductase (MTHFR)
and the p.Asp7Asn allele in ChAT, encoding choline O-acetyltransferase, with both
alleles having been shown to confer an elevated susceptibility to psychoses. We have
found thousands of other variants in his genome, including pharmacogenetic and
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ABSTRACT
Background. In recent years, there has been an explosion in the number of technical
and medical diagnostic platforms being developed. This has greatly improved our
ability to more accurately, and more comprehensively, explore and characterize
human biological systems on the individual level. Large quantities of biomedical
data are now being generated and archived in many separate research and clinical
activities, but there exists a paucity of studies that integrate the areas of clinical
neuropsychiatry, personal genomics and brain-machine interfaces.
Methods. A single person with severe mental illness was implanted with the
Medtronic Reclaim® Deep Brain Stimulation (DBS) Therapy device for Obsessive
Compulsive Disorder (OCD), targeting his nucleus accumbens/anterior limb of the
internal capsule. Programming of the device and psychiatric assessments occurred
in an outpatient setting for over two years. His genome was sequenced and vari-
ants were detected in the Illumina Whole Genome Sequencing Clinical Laboratory
Improvement Amendments (CLIA)-certified laboratory.
Results. We report here the detailed phenotypic characterization, clinical-grade
whole genome sequencing (WGS), and two-year outcome of a man with severe
OCD treated with DBS. Since implantation, this man has reported steady improve-
ment, highlighted by a steady decline in his Yale-Brown Obsessive Compulsive Scale
(YBOCS) score from⇠38 to a score of⇠25. A rechargeable Activa RC neurostimula-
tor battery has been of major benefit in terms of facilitating a degree of stability and
control over the stimulation. His psychiatric symptoms reliably worsen within hours
of the battery becoming depleted, thus providing confirmatory evidence for the
eYcacy of DBS for OCD in this person.WGS revealed that he is a heterozygote for the
p.Val66Met variant in BDNF, encoding a member of the nerve growth factor family,
and which has been found to predispose carriers to various psychiatric illnesses.
He carries the p.Glu429Ala allele in methylenetetrahydrofolate reductase (MTHFR)
and the p.Asp7Asn allele in ChAT, encoding choline O-acetyltransferase, with both
alleles having been shown to confer an elevated susceptibility to psychoses. We have
found thousands of other variants in his genome, including pharmacogenetic and
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Figure 1 Sagittal and transverse computed tomography (CT) images of the brain and skull ofMA.We
show here sagittal and transverse sections taken from CT scans. Imaging was performed before (A) and
after (B) MA received deep brain stimul tion surg ry for his treatment refractory OCD. Two deep brain
stimulator probes can be see to be in place from a bifr ntal approach (B), with tips of the probes located
in t e region f the hypothalamus. L ads traverse through the left scalp soft tissues. Streak artifact from
the leads somewh t obscures visualization of the adjac nt bifrontal and left parietal parenchyma. We did
not observe any intracranial hemorrhage, mass eVect or midline shift r extra-axial fluid collection. Brain
parenchyma was n rmal in volume and contour.
DBS implant has contributed to any of these issues. Attempts to add fluoxetine at 80 mg
by mouth daily for two months to augment any eYcacy from the DBS and ERP were
unsuccessful, mainly due to no discernible benefit and pro inent sexual side eVects. MA
still receives an injection of 37.5 mg risperidone every two weeks for his past history of
O’Rawe et al. (2013), PeerJ, DOI 10.7717/peerj.177 8/26
A	  family	  in	  Utah,	  with	  a	  40	  year	  old	  Caucasian	  man	  
with	  
very	  severe	  obsessive	  compulsive	  disorder,	  severe	  
depression	  and	  intermiTent	  paranoia,	  with	  symptoms	  
that	  started	  around	  age	  5.	  
	  
Some	  people	  had	  diagnosed	  him	  with	  bipolar	  and/or	  
schizophrenia	  due	  to	  his	  mood	  states	  and	  possible	  
paranoia.	  
	  
Mul=ple	  medica=on	  trials	  failed	  over	  many	  years.	  	  
Considered	  treatment	  refractory.	  
	  
Pedigree	  structure	  
Humanitarian	  Device	  Exemp=on	  (HDE)	  
for	  OCD	  granted	  by	  FDA	  in	  2009	  
symptoms, and psychosis has also been re-
ported with STNDBS in Parkinson patients
(114, 115, 126). DBS of the globus pallidus
interna has demonstrated anxiolytic effects
(46). Globus pallidus interna DBS has also
been associated with relief of depressive
symptoms in a patient with dyskinesia (63).
Although DBS is widely used in move-
ment disorders, fewer studies have investi-
gated its use specifically to treat psychiatric
disorders. Effects of DBS have been re-
ported in approximately 100 OCD patients
and approximately 50 patients with depres-
sion; response rates appear to exceed 50%.
Also, multiple targets have shown efficacy
for approximately 40 patients with Tourette
syndrome (20). The large number of sites
and few cases for each site preclude full dis-
cussion here. The limited data for DBS in
psychiatric disorders is also reflected by its
regulatory status; thalamic DBS for essen-
tial tremor received Food and Drug Admin-
istration approval in 1997 and STN DBS for
Parkinson was approved in 2002 followed
by globus pallidus interna DBS for Parkin-
son in 2003. Currently, the only psychiatric
disorder with Food and Drug Administra-
tion status isOCD,which, like dystonia, has
been granted a humanitarian device exemp-
tion.One additional concern for psychiatric
disorders is the delay in time to respond
following stimulation initiation. In this
context, frequent follow-up is indicated for
DBS in psychiatric disorders. Also, to limit
risks of inducing hypomania, patients
shouldbe encouraged to remain close to the
programming physician overnight follow-
ing adjustments, particularly if traveling
from far away.
The first reports of DBS treatment pri-
marily for psychiatric conditions,OCD, and
Tourette syndrome, were published in The
Lancet in 1999 (88, 120). Stimulation of the
anterior limb of the internal capsule in “tar-
gets [that] were identical to those aimed for
in capsulotomy” led to symptomatic im-
provement in three of four patients with re-
sistant OCD. Specific scale scores were not
published, but the authors state that one
patient’s parents reported 90% improve-
ment in her compulsive behaviors and ritu-
als after 2 weeks of stimulation. Data from
six OCD patients who received double-
blinded, bilateral internal capsular stimula-
tion were published in 2003 (89). These pa-
tients all had severe symptoms at baseline
as indicated by Y-BOCS scores !30 and
Global Assessment of Function scores 45.
The location of tip center in the patient with
best clinical response was reported as 3.5
mmanterior to the anterior commissure, 13
mm lateral to themidline on left and 14mm
lateral to midline on right, and at the level
of the intercommissural plane. Although
contacts 1 and 2 were in the internal cap-
sule, the most distal electrode, contact 0,
was in or near the NAc whereas the most
proximal, contact 3, was dorsal to the inter-
nal capsule.With constant stimulation, 3 of
6 patients met response criteria of 35% re-
duction inY-BOCS; the authors suggest that
nonresponse in one patient may be related
to a comorbid somatoform disorder. When
stimulationwas turnedoff, all threeof these
responders experienced significant wors-
ening of mood and OCD symptoms. The
three responders also showed reductions in
frontal metabolism, assessed by PET, after
3 months of stimulation. In 2008, these
data were republished with data from 2 re-
cently implanted patients and additional
follow-up (90).No infections, deaths, hem-
orrhages, or significant changes in vegeta-
tive function were seen. Also, no mania oc-
curred though some disinhibition that
responded to decreases in stimulation in-
tensity was noted.
STN DBS was published for 16 patients
in a multicenter 10-month, double-blind,
crossover study (76).One additional patient
was implanted in this study but postopera-
tive infection required explantation prior to
randomization and assessment. Decreases
in Y-BOCS and Clinical Global Impression
scores, along with increases in Global As-
sessment of Function scores, were signifi-
Figure 10. DBS electrode. Medtronic DBS lead and microelectrode. (Courtesy of Medtronic Inc.)
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Figure 1
Three-dimensional (3D) illustration of bilaterally implanted deep brain stimulation (DBS) electrodes in the ventral capsule/ventral
striatum. The 3D objects (leads and brain structures) are sitting on the axial plane 5 mm below the AC–PC plane as viewed posterior to
anterior. The trajectory of the leads is down the barrel of the anterior limb of the internal capsule. Each lead has four contacts, but only
three are shown (contacts #0, #1, and #2); contact #3 is hidden by the caudate nucleus. The most ventral #0 contact is active, as
represented by red radiating stimulation fields. Abbreviations: AC–PC, anterior commissure–posterior commissure; GPe, globus
pallidus externus; GPi, globus pallidus internus. Image courtesy of Kirk Finnis, PhD (Medtronic Inc., USA).
ALIC: anterior limb
of the internal capsule
NAc: nucleus
accumbens
SCG: subcallosal
cingulate gyrus
STN: subthalamic
nucleus
place. The second stage is conducted under
general anesthesia either immediately or within
days following completion of the first stage.
The surgical techniques employed to im-
plant DBS devices for the treatment of psy-
chiatric disorders are derived from the vast ex-
perience of performing both ablative and DBS
surgery for movement disorders. In several re-
spects, the therapeutic sites for treating psychi-
atric disorders are easier to target than those for
movement disorders. First, the most common
targets—e.g., the anterior limb of the internal
capsule (ALIC), the nucleus accumbens (NAc),
and the subcallosal cingulate gyrus (SCG;Brod-
mann’s area 25)—are larger and more readily
visualized on T1-weighted magnetic resonance
imaging (MRI) than are the sites that are stim-
ulated to treat movement disorders, such as the
subthalamic nucleus (STN). Second, these tar-
gets are located in brain regions where DBS
is less likely to induce obvious adverse effects
(e.g., muscular contractions, painful paresthe-
siae, eye deviations) that would limit the clini-
cal efficacy of stimulation. One exception is hy-
pomania, which has been observed with ALIC
stimulation (see “Complications of Surgery”
below). Third, the lack of an immediate pos-
itive clinical response to stimulation allows
the surgery to be performed with the patient
fully asleep or consciously sedated—although
the “smile reflex” (12) may prove to represent
just such a positive clinical indicator (13). Of
course, the lack of an immediate therapeutic re-
sponse to stimulation also poses a disadvantage,
as there is no intraoperative feedback to the
surgeon that the therapeutic site has been
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Abstract
Deep brain stimulation (DBS) has virtually replaced ablative neuro-
surgery for use in medication-refractory movement disorders. DBS is
now being studied in severe psychiatric conditions, such as treatment-
resistant depression (TRD) and intractable obsessive-compulsive disor-
der (OCD). Effects of DBS have been reported in ∼100 cases of OCD
and ∼50 cases of TRD for seven (five common) anatomic targets. Al-
though these published reports differ with respect to study design and
methodology, the overall response rate appears to exceed 50% in OCD
for some DBS targets. In TRD, >50% of patients responded during
acute and long-term bilateral electrical stimulation in a different target.
DBS was generally well tolerated in both OCD and TRD, but some
unique, target- and stimulation-specific adverse effects were observed
(e.g., hypomania). Further research is needed to test the efficacy and
safety of DBS in psychiatric disorders, compare targets, and identify
predictors of response.
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Figure 1 Sagittal and transverse computed tomography (CT) images of the brain and skull ofMA.We
show here sagittal and transverse sections taken from CT scans. Imaging was performed before (A) and
after (B) MA received deep brain stimulation surgery for his treatment refractory OCD. Two deep brain
stimulator probes can be seen to be in place from a bifrontal approach (B), with tips of the probes located
in the region of the hypothalamus. Leads traverse through the left scalp soft tissues. Streak artifact from
the leads somewhat obscures visualization of the adjacent bifrontal and left parietal parenchyma. We did
not observe any intracranial hemorrhage, mass eVect or midline shift or extra-axial fluid collection. Brain
parenchyma was normal in volume and contour.
DBS implant has contributed to any of these issues. Attempts to add fluoxetine at 80 mg
by mouth daily for two months to augment any eYcacy from the DBS and ERP were
unsuccessful, mainly due to no discernible benefit and prominent sexual side eVects. MA
still receives an injection of 37.5 mg risperidone every two weeks for his past history of
O’Rawe et al. (2013), PeerJ, DOI 10.7717/peerj.177 8/26
2.5	  year	  follow-­‐up	  
Figure 2.   Yale Brown Obsessive Compulsive Scale (YBOCS) scores were measured 
for M.A  over a three year and seven months period of time.  A time series plot (A) 
shows a steady decline in YBOCS scores over the period of time spanning his DBS surgery 
(s) and treatment.   Incremental adjustments to neurostimulator voltage are plotted over a 
period of time following DBS surgery (A).  Mean YBOCS scores are plotted for sets of 
measurements taken before and after his Deep Brain Stimulation (DBS) surgery (B).  A 
one-tailed  unpaired  t  test  with  Welch’s  correction  results  in  a  p  value  of 
0.0056,  demonstrating  a significant difference  between YBOCS scores measured before 
and after the time of surgery.	
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Depleteable	  nature	  of	  baTery	  
•  BaTery	  replaced	  with	  a	  rechargeable	  baTery	  
in	  January	  2012.	  
•  Numerous	  episodes	  of	  forgegng	  to	  recharge	  
baTery,	  with	  relapse	  to	  baseline	  condi=on.	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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more significant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the field of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a significant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efficacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
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entirely performed on Illumina equipment using one of a few library
preparation methods, with 100 base paired-end sequencing performed
in the major research sequencing centers to an average depth of 70–
100× to achieve >80% of the target region covered by 20 or more
reads. Others havemade suggestions for standardizing exome sequenc-
ing (Klein et al., 2012), and we believe it is high-time to establish such
standards, at least for exomes being sequenced from live human beings,
so that results can be returned to participants.
However, while sequencing is relatively standardizable, it is true
that many of the downstream processes are not, as bioinformatics
analyses and interpretive schemes can be extremely variable. While
the desired informatics and interpretive analysis for healthy individ-
uals might focus on alleles relevant for future disease risk, carrier sta-
tus and pharmacogenomics, genomic analyses for rare diseases might
instead focus on de novo, homozygous or X-linked disease variants,
possibly in the context of a parent–child trio or preferably in the con-
text of even larger families, including grandparents. Certain findings
seen in one patient may escape detection in another patient simply
due to differences in the basic strategy of analysis or the phenotype
of the individuals. With respect to population studies, the analytical
variation can be tremendous, with focuses ranging from ethnicity-
specific variation to variation associated with complex disease, basic
human phenotypes and evolutionary processes. The number of differ-
ent performable analyses is limited only by the imagination.While the
informed consent process for each individual study would be required
to include a discussion of the analysis details, the process can be con-
fusing for participants and easily leave them at the end unclearwheth-
er or not particular findings were investigated and frustrated by an
inability to access the data. This being the case, it would be beneficial
to move towards a systemwhereby a straightforward clinical analysis
of data from research projects could be subsequently performed at a
later time, within a proper regulatory framework.
This downstream variation in informatics and interpretation raises
an important question: from the clinical standpoint, what exactly con-
stitutes a genetic laboratory test? Is it simply the analytics (the se-
quencing), or is it a combination of analytics and interpretation, or is
it the entire process from sample receipt through to the generation
and return of a report? Here, the legal definition is really quite
clear, as CLIA specifically states that a medical laboratory test is an all-
encompassing process (Anon., 2013a). The introduction to CLIA subpart
K states that “each laboratory that performsnonwaived testingmust es-
tablish and maintain written policies and procedures that implement
and monitor quality systems for all phases of the total testing process
(that is, preanalytic, analytic, and postanalytic) as well as general labo-
ratory systems” (see Table 1 for a summary of the analytic systems).
It is noteworthy that test interpretation and reporting are specifi-
cally covered by the CLIA statutes and included as part of the regulated
test process. This is important because, as the community has discov-
ered, the actual sequencing has become increasingly straightforward,
whereas the true difficulties and pitfalls lie in the informatics, inter-
pretation and reporting. Any meaningful regulatory framework for
NGS-based diagnostics must include oversight of informatics path-
ways and interpretive criteria, as there are simply too many ways to
do informatics incorrectly, with resultant possibilities for harm to pa-
tients and participants.
This issue is beginning to get the attention of the agencies respon-
sible for overseeing clinical laboratories, now that a large number of
clinical laboratories have begun developing a variety of tests on NGS
instruments. The College of American Pathologists (CAP) has recently
released a new checklist for molecular pathology laboratories that
includes both general laboratory and test development guidelines
covering NGS wet lab practices, bioinformatics processing and data
storage and transfer practices. Additionally, the New York State De-
partment of Health Clinical Laboratory Evaluation Program (CLEP)
has issued detailed guidelines for the development and validation of
NGS cancer genomics assays (Anon., 2013b). New York is one of
two CLIA-exempt states as a result of its own state licensure regula-
tions being deemed “equal to, or more stringent than” CLIA by CMS
per CLIA subpart E, thus clinical laboratories in New York receive
their CLIA license through th tate following s ccessful state certifi-
cation. The CLEP NGS oncology guidelines are quite thorough, includ-
ing requirements for quality scores, control procedures, acceptabl
numbers of sp cimens for valid tion studies and guideli es for
stablishi g read dep , accuracy, sensitivity, tc., focusing on actual
performance rather than the details of bioinformatics pipelines. Over-
all, the regulatory framework for NGS on the pure clinical side is com-
ing together, with certain aspects such as reporting criteria hopefully
being sorted out in the near future.
However, if a clinical NGS test is defined by both the sequencing
and downstream informatics, and the informatics possibilities for a
standar equence are essentially limitless, how could CLIA supervi-
sion be applied to combined research and clinical genomics operations
without placi g an extreme regu atory burden on the sequencing
laboratory? Would every analysis type need to be certified, or would
a time-consuming standardized analysis be required even if it were
not needed for each p rticular peration?
6. The distributive model: an analytical-interpretive split
across genomics
Any ideal solution would allow sequencing centers to focus on
their strengths and to leverage their economies of scale, without re-
quiring them to devote their time to unnecessary informatics and in-
terpretation. How can that be achieved in keeping with the spirit of
proper CLIA oversight? As a solution, we would propose an analytic-
interpretive split (or a so-called “distributivemodel”) across both clin-
ical and research genomics. This split model simply means that one
laboratory performs analytics and then a second laboratory performs
the interpretation and reporting. Thus, together, the two laboratories
perform all the functions that make up a laboratory test. This should
be a straightforward arrangement, but while some precedent and
guidance policies exist, the regulatory structure that would govern
such a system is still evolving, as we will discuss.
The benefits of enacting such a split model could be substantial,
and we believe they could be gained without significantly burdening
our sequencing centers with undue excess costs. Under this type of
system, the basic sample processing and sequencing operation could
be standardized across clinical patients and the majority of new geno-
mics research participants. The practical effect of this split would be
to turn an exome or genome sequence into a discrete deliverable unit
that could be used for multiple downstream purposes by multiple
downstream labs. For each patient or participant, the same validated
sequencing would be performed, and that raw data, if individually
Table 1
Processes involved in a CLIA-certified genetic test.
Preanalytic system
1) Test request and specimen collection criteria
2) Specimen submission, handling and referral procedures
3) Preanalytic systems assessment
Analytic system
1) A detailed step-by-step procedure m nual
2) Test systems, equipment, instrum nts, reagents, mat rials and
supplies
3) Establishment and verification of performance specifications
4) Maintenance and function checks
5) Calibration and calibration verification procedures
6) Control procedures, test records, and corrective actions
7) Analytic systems assessment
Post-analytic system
1) Test report, including (among other things):
a) interpretation
b) reference ranges and normal values
2) Post-analytic systems assessment
4 G.J. Lyon, J.P. Segal / Applied & Translational Genomics xxx (2013) xxx–xxx
Please cite this article as: Lyon, G.J., Segal, J.P., Practical, ethical and regulatory considerations for the evolving medical and research genomics
landscape, Applied & Translational Genomics (2013), http://dx.doi.org/10.1016/j.atg.2013.02.001
1.	  Sample	  Collec=on	  and	  handling	  
	  
	  
2.	  Sequencing/Analy=cs	  
	  
	  
3.	  Interpreta=on	  
“This	  laboratory	  test	  was	  developed,	  and	  its	  performance	  characteris;cs	  
were	  determined	  by	  the	  Illumina	  Clinical	  Services	  Laboratory	  (CLIA-­‐cer;fied,	  
CAP-­‐accredited).	  Consistent	  with	  laboratory-­‐developed	  tests,	  it	  has	  not	  been	  
cleared	  or	  approved	  by	  the	  U.S.	  Food	  and	  Drug	  Administra;on.	  If	  you	  have	  
any	  ques;ons	  or	  concerns	  about	  what	  you	  might	  learn	  through	  your	  genome	  
sequence	  informa;on,	  you	  should	  contact	  your	  doctor	  or	  a	  gene;c	  
counselor.	  Please	  note	  that	  Illumina	  does	  not	  accept	  orders	  for	  Individual	  
Genome	  Sequencing	  services	  from	  Florida	  and	  New	  York.”	  

Sample	  Collec=on	  and	  Handling	  	  
The	  Sample	  Collec=on	  kit	  includes	  barcoded	  collec=on	  tubes,	  a	  
Test	  Requisi=on	  form,	  an	  Informed	  Pa=ent	  Consent	  form,	  and	  a	  pre-­‐paid	  
shipping	  envelope.	  All	  paperwork	  must	  be	  completed	  and	  returned	  for	  
sample	  processing.	  Requests	  for	  Sample	  Collec=on	  kits	  must	  be	  
submiTed	  by	  a	  physician.	  
hTp://www.illumina.com/clinical/illumina_clinical_laboratory/igs_for_doctors/
how_to_order.ilmn	  
	  
Sequencing	  and	  Analy=cs	  
From	  the	  Illumina	  Understand	  
Your	  Genome	  Symposium	  
October	  2012	  
Figure 2 Implementation of the analytic-interpretive split model for the clinical incorporation of a
whole genome. We have implemented the analytic-interpretive split model here with MA, with WGS
being performed in a CLIA certified and CAP accredited lab at Illumina as part of the Individual Genome
Sequencing test developed by them. The WGS acts as a discrete deliverable clinical unit from which
multiple downstream interpretive analyses were performed. We used the ERDS CNV caller, the Golden
Helix SVS CNAM for CNV calling, and the Omicial Opal and the AssureRx Health Inc. pipelines for
variant annotation and clinical interpretation of genomic variants. By archiving and oVering to him
the encrypted hard drive containing his “raw” sequencing data, any number of people, including the
individual and/or his/her health care providers can analyze his genome for years to come. Abbreviations:
CLIA, Clinical Laboratory Improvement Amendments; CAP, College of American Pathologists; CASAVA,
Consensus Assessment of Sequence and Variation; ERDS, Estimation by Read Depth with SNVs; CNAM,
Copy Number Analysis Method; WGS, Whole Genome Sequencing.
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Evalua=on	  of	  344	  genes	  by	  Illumina	  
Refsum	  Disease?	  
•  Referred	  to	  optometry	  for	  further	  evalua=on	  
of	  this.	  
•  Found	  to	  have	  bilateral	  cataracts,	  large	  pupils,	  
and	  loss	  of	  night	  vision.	  
•  His	  mother	  and	  grandfather	  both	  have	  large	  
pupils	  and	  loss	  of	  night	  vision.	  No	  cataracts	  
known.	  
•  Preven=ve	  measures	  implemented	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Figure 2. Flow chart of our variant analysis pipeline. 
* Both Scalpel and CADD are still inpress. For CADD,  see http://cadd.gs.washington.edu/
Some	  genomic	  analysis	  online	  plalorms	  and	  analysis	  suites	  
Descrip=on:	  Prion	  Disease,	  Suscep=bility	  
To	  Alzheimer	  Disease,	  Early-­‐onset,	  
Suscep=bility	  To,	  Included,,	  Aphasia,	  
Primary	  Progressive,	  Suscep=bility	  To,	  
Included	  
cancer-­‐associated	  
	  Pseudoxanthoma	  elas=cum	  
Viral	  infec=ons,	  recurrent,	  suscep=bility	  
to	  
Condi=on:	  Hypertension,	  essen=al,	  
suscep=bility	  to	  
Descrip=on:	  Reduced	  melormin	  uptake	  
in	  transfected	  cells	  
associated	  with	  shorter	  bleeding	  =me	  
and	  less	  response	  to	  aspirin.	  	  
a	  higher	  risk	  of	  secondary	  coronary	  
events	  which	  was	  reduced	  by	  
pravasta=n	  
associated	  with	  blood	  pressure	  
response	  to	  nifedipine	  treatment.	  
Easily	  select	  variants	  with	  prior	  evidence	  
	  
	  
	  
	  
	  
	  
Assurex	  /	  Mayo	  Clinic	  Pharmacogenomics	  Pipeline	  
Input	  Whole	  Genome	  Data	  
1.  Check	  coding	  single	  nucleo=de	  variants	  
and	  structural	  variants	  in	  exons	  of	  
candidate	  genes;	  
2.  Check	  genome	  variants	  within	  
intergenic,	  intronic,	  5’UTR	  and	  3’	  UTRs;	  
3.  Check	  pharmacoepigenomic	  variants,	  
emphasizing	  TF	  binding	  mo=fs;	  
4.  Check	  epistasis	  and	  LD;	  
5.  Determine	  allele	  frequency.	  
Literature	  
	  
Manual	  Analysis	  
	  
Search	  Strings	  
Weighted	  
Heatmap	  
	  
Semi-­‐automated	  Analysis	  
	  
Natural	  
Language	  
Processing	  of	  
Clinical	  Trials	  
Manual	  Cura;on	  of	  Output	  
Gerry	  Higgins,	  MD,	  PhD	  
Pharmacogene=cs	  
u MA	  is	  homozygous	  for	  a	  p.Ile359Leu	  change	  in	  CYP2C9,	  and	  this	  
variant	  has	  been	  linked	  to	  a	  reduc=on	  in	  the	  enzyma=c	  ac=vity	  of	  
CYP2C9,	  a	  member	  of	  the	  cytochrome	  P450	  superfamily	  of	  
enzymes.	  	  
	  
u Fluoxe=ne	  is	  commonly	  used	  in	  the	  treatment	  of	  OCD;	  it	  has	  been	  
shown	  to	  be	  as	  effec=ve	  as	  clomipramine	  and	  causes	  less	  side	  
effects.	  	  
u CYP2C9	  acts	  to	  convert	  fluoxe=ne	  to	  R-­‐norfluoxe=ne,	  and	  so	  MA	  
may	  not	  be	  able	  to	  adequately	  biotransform	  fluoxe=ne.	  
u  It	  is	  notable	  that	  MA	  had	  no	  response	  to	  an	  80	  mg	  daily	  dose	  of	  
fluoxe=ne.	  
	  
No	  rare	  variants	  or	  CNVs	  with	  high	  biological	  effect	  as	  related	  to	  
mental	  illness.	  	  
	  
Here	  are	  3	  common	  SNVs	  in	  this	  person	  that	  have	  been	  
implicated	  in	  the	  literature	  as	  predisposing	  to	  mental	  illness.	  
Table 1 A summary of three clinically relevant alleles found in the sequencing results of MA. Variations in MTHFR, BDNF, and ChAT were
found to be of potential clinical relevance for this person as they are all implicated in contributing to the susceptibility and development of many
neuropsychiatric disorders that resemble those present within MA. A brief summary of the characteristics of each variation is shown, including the
gene name, genomic coordinates, amino acid change, zygosity, variation type, estimated population frequency and putative clinical significance.
Gene
name
Genomic
coordinates
Amino acid
change
Zygosity Variation
type
Population
frequency
Clinical significance
MTHFR chr1: 11854476 Glu> Ala heterozygous non-synon T:77% G:23% Susceptibility to psychoses, schizophrenia
occlusive vascular disease, neural tube defects,
colon cancer, acute leukemia, and methylenetetra-
hydrofolate reductase deficiency
BDNF chr11: 27679916 Val>Met heterozygous non-synon C:77% T:23% Susceptibility to OCD, psychosis, and diminished
response to exposure therapy
CHAT chr10: 50824117 Asp> Asn heterozygous non-synon G:85% A:15% Susceptibility to schizophrenia and other psy-
chopathological disorders.
be given the opportunity, like with many other traditional medical tests, to obtain “second
opinions”. For this to be possible, one must accurately describe the contents of short-read
sequencing data in terms of the existing electronic medical health standards, so that these
data can be incorporated into an electronic medical health record. Accurately describing
the contents of next generation sequencing (NGS) results is particularly critical for
clinical analysis of genomic data. However, genomics and medicine use diVerent and
often incompatible terminologies and standards to describe sequence variants and their
functional eVects. In our eVorts to treat this one person with severe mental illness, we
have implemented the GVFclin format for the variants that were discovered during the
sequencing of his whole genome (see File S12). We hope to eventually incorporate his
genetic data into his electronic health record if and when the VistA health information
system (HIS) (Conn, 2011; Protti & Groen, 2008; Kuzmak & DayhoV, 1998; Brown et al.,
2003) is upgraded to allow entry of such data.We did already counsel MA regarding several
genetic variants that may be clinically relevant to predisposing him to his psychiatric
disorder (Biesecker & Peay, 2013).
Returning genetic results
There is considerable controversy in the field of medical genetics concerning the extent of
return of genetic results to people, particularly in the context of “secondary”, “unrelated”,
“unanticipated” or “incidental” findings stemming from new high-throughput sequencing
techniques (Lyon, 2012c). Some people have concerns regarding the clinical utility
of much of the data, and in response have advocated for selectively restricting the
returnable medical content. One such set of recommendations has been provided by
the American College ofMedical Genetics which recently released guidelines in which they
recommended the “return of secondary findings” for 57 genes, without detailed guidance
for the rest of the genome (Green et al., 2013). These types of recommendations take
a more paternalistic approach in returning test results to people, and generally involve
a deciding body of people that can range in size from a single medical practitioner to
a committee of experts. We believe that anyone should be able to access and manage
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Q:	  How	  frequent	  can	  we	  observe	  people	  
with	  all	  three	  SNPs?	  
•  Empirical	  genotype	  frequencies:	  	  
•  1000G:	  3.20%	  (35	  out	  of	  1092,	  phenotypes	  unknown)	  	  
•  UFBR:	  4.58%	  (7	  out	  of	  153,	  including	  M.A.	  and	  M.A.’s	  father)	  
Ripke	  et.al	  (2013)	  Nature	  Gene=cs	  
Ripke	  et.al	  (2013)	  Nature	  Gene=cs	  
Disrup;ve	  developments	  
Pa;entsLikeMe	  
Preven=on	  efforts,	  genomics-­‐guided	   More	  direct	  ac=on	  on	  the	  brain	  itself	  
Figure 1 Sagittal and transverse computed tomography (CT) images of the brain and skull ofMA.We
show here sagittal and transverse sections taken from CT scans. Imaging was performed before (A) and
after (B) MA received deep brain stimulation surgery for his treatment refractory OCD. Two deep brain
stimulator probes can be seen to be in place from a bifrontal approach (B), with tips of the probes located
in the region of the hypothalamus. Leads traverse through the left scalp soft tissues. Streak artifact from
the leads somewhat obscures visualization of the adjacent bifrontal and left parietal parenchyma. We did
not observe any intracranial hemorrhage, mass eVect or midline shift or extra-axial fluid collection. Brain
parenchyma was normal in volume and contour.
DBS implant has contributed to any of these issues. Attempts to add fluoxetine at 80 mg
by mouth daily for two months to augment any eYcacy from the DBS and ERP were
unsuccessful, mainly due to no discernible benefit and prominent sexual side eVects. MA
still receives an injection of 37.5 mg risperidone every two weeks for his past history of
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•  “We	  are	  visi=ng	  Town	  X	  on	  the	  Island	  of	  X.	  	  
Interes=ngly,	  I	  toured	  the	  "mental	  hospital	  "	  
here	  yesterday.	  	  It	  was	  a	  sad	  reminder	  of	  how	  
pa=ents	  in	  America	  used	  to	  suffer	  and	  how	  they	  
s=ll	  do	  in	  most	  areas	  of	  the	  world.	  	  	  	  It	  made	  me	  
even	  more	  grateful	  that	  M.A.	  had	  the	  very	  best	  
in	  medical	  care	  and	  is	  now	  living	  a	  nearly	  
normal	  life”.	  
Feedback	  from	  M.A.’s	  
mother	  
